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Background: Deep brain stimulation (DBS) is emerging as a promising tool in the treatment of refractory
obsessive-compulsive disorder (OCD) but the search for the best target still continues. This issue is especially
relevant when particularly resistant profiles are observed in some patients, which have been ascribed to individual
responses to DBS according to differential patterns of connectivity. As patients have been implanted, new
dilemmas have emerged, such as what to do when the patient does not respond to surgery.
Case presentation: Here we describe a 22-year-old male with extremely severe OCD who did not respond to
treatment with DBS in the nucleus accumbens, but who did respond after explanting and reimplanting leads
targeting the ventral capsule-ventral striatum region. Information regarding the position of the electrodes for both
surgeries is provided and possible brain structures affected during stimulation are reviewed. To our knowledge this
case is the first in the literature reporting the removal and reimplantation of DBS leads for therapeutical benefits in
a patient affected by a mental disorder.
Conclusion: The capability for explantation and reimplantation of leads should be considered as part of the DBS
therapy reversibility profile in resistant mental disorders, as it allows application in cases of non-response to the first
surgery.
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The scientific and ethical issues in the application of deep
brain stimulation (DBS) in resistant psychiatric disorders
continue to be debated (reviewed in [1]). In the case of
obsessive-compulsive disorder (OCD), ablative psychosur-
gery has been the last-resort treatment for refractory
patients in recent decades [2]. However, the therapeutic
benefits reported for this approach are clouded by its
potential adverse effects, especially impairment in frontal
lobe functioning [3, 4]. In this context, DBS has emerged* Correspondence: gplans@bellvitgehospital.cat
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ablative surgery in resistant OCD and depression.
As patients have been implanted, new dilemmas have
emerged, such as what to do when the patient does not
respond to surgery. Device removal is often required for
clinical cure when leads or generator pocket infection
occurs. This procedure (and device reimplantation) has
been previously reported for movement disorders [5–7],
but not for therapeutical purposes in mental disorders.
The patient described here is a treatment-refractory OCD
participant on a DBS treatment program run by at the
OCD Clinical and Research Unit of Bellvitge University
Hospital. He was explanted and reimplanted (in a different
location and using different leads) due to very low thera-
peutic benefit after the first surgery.distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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Clinical history
A 22-year-old male with extremely severe OCD underwent
DBS and pulse generator implantation in September 2009.
The patient and his family reported severe obsessive-
compulsive symptomatology since childhood: at 11 he
began to manifest magical thoughts and compulsions in-
volving “just-right” symptoms, symmetry and perfection-
ism, slowness in writing, the need to hoard and to touch
objects, and repeating and arranging rituals. The disease
course had been progressively debilitating, with highly com-
pulsive time wasting behavior that led to the abandonment
of education and successive hospital admissions from the
age of 13. After trying a wide variety of treatments the
patient was enrolled on the DBS program. For reasons of
space, some features of the case (as well as treatment resist-
ance profile) are summarized in the Table 1.
First DBS surgery
Surgical procedure was performed according to Bell-
vitge Hospital DBS protocol for resistant OCD (L.D.
B-29406-2012). The study protocol was approved by
the ethics committee of Bellvitge University Hospital
(CEIC Ciutat Sanitària i Universitària de Bellvitge).Table 1 Patient characteristics and stimulation settings
Sex
Age at OCD Onset
Age at surgery
Worst YBOCS ever
Worst HDRS ever
Pharmacological
resistance profile1
Fluoxetine 60 mg/dFluvoxamine
300 mg/dSertraline 200 mg/
dEscitalopram 20 mg/
dClomipramine 300 mg/d
1st Surgery
Treatment2 CLM 262.5 mg/d + ESCIT
20 mg/d + RIS 1.5 mg/d +
AGOM 25 mg/d
Stimulation settings 0 + 1-, 210 μs, 135 Hz, 4 V 4 + 5-, 210 μs, 1
Best YBOCS reached 35
Best HDRS reached 12
Best GAF reached 30
Position of the
center of the
stimulation*
Left (0–1) Right (4–5)
x 5,29 10,54
y 5,47 3,54
z −4,26 −0,85
1Pharmacological resistance profile refers to all the different pharmacological trials
11 years old until he performed the first surgery). Doses of these drugs were maint
2Treatment refers to the precise combination of drugs that the patient was taking w
*Distance from the anterior commissure (AC)
Abbreviations: OCD obsessive-compulsive disorder, Y-BOCS Yale-Brown Obsessive Co
Assessment Functioning scale, CLM clomipramine, ESCIT escitalopram, RIS risperidonTwo quadripolar DBS electrodes (Model 3389 DBS
lead; Medtronic, MN, USA) were bilaterally implanted
in the nucleus accumbens (NAcc) region with the aid
of a Leksell stereotactic frame (Elekta, Sweden). NAcc
was one of the targets reported to be effective in the
treatment of OCD with DBS [8, 9] and 3389 elec-
trode was the one available in our setting at that mo-
ment. The target was referenced to the anterior
commissure (AC) as described in previous studies [9].
The stereotactic brain surgery software BrainLab iPlan
Stereotaxy 1.1 (Brain Lab, Germany) was used for tar-
get selection and trajectory planning. A postoperative
stereotactic cranial CT scan was co-registered with
the preoperative MRI to verify the final position of
the electrodes within the first 24 hours. The position
of each contact was referenced to the AC and coordi-
nates were transferred to an anatomic atlas [10] to
identify anatomic structure influenced during stimula-
tion. The final position of the active contacts with re-
spect to AC is shown in the Table 1.
Even though parameter testing and adjustment were
the same as in other DBS implanted patients, no sig-
nificant clinical improvements were achieved with the
first surgery (Y-BOCS reduction from 38 to 35, lessMale
11
19
38
12
Venlafaxxine 150 mg/dPhenelzine
60 mg/dPimozide 2 mg/
dRisperidone 3 mg/dAmisulpride
200 mg/dAripiprazole 15 mg/d
2nd Surgery
CLM 265.5 mg/d + ESCIT 40 mg/d + RIS 1.5 mg/d
35 Hz, 4 V 0-1+, 270 μs, 60 Hz, 3 V 5-6+, 270 μs, 60 Hz, 3 V
26
7
65
Left (0–1) Right (5–6)
9,02 8,57
−3,12 −4,46
2,87 −1,32
conducted during the whole follow-up (since the patient was first treated at
ained for at least 12 weeks, to complete the trials
hen the best Y-BOCS and HDRS scores were achieved
mpulsive Scale, HDRS Hamilton Depression Rating Scale, GAF Global
e, AGOM agomelatine, x lateral, y anteroposterior, z axial
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life remained very poor, and he needed further hos-
pital admissions after DBS surgery. After a full ex-
planation and with the consent of the patient and his
family, the DBS electrodes were removed in March
2011. In April 2011 the patient underwent surgery for
the second time. A baseline-assessment between the two
implantations was done and clinical and psychometric
measurements were performed (i.e.: Y-BOCS ratings
dropped to the first intervention’s previous levels).
Second DBS surgery
For the second surgical procedure we decided to use the
ventral capsule/ventral striatum (VC/VS) target as it was
reported to have the strongest evidence for therapeutic
benefits at that moment [11]. The final theoretical target
was calculated to be at the posterior border of the AC at
the intercommissural level and 5 mm lateral to midline.
The final trajectory was planned to cover the whole
length of the anterior limb of the internal capsule
(ALIC). For this purpose a Model 3391 DBS lead was
used (the aim was to increase the setting options of the
electric field, mainly in size, seeking the highest potential
for clinical benefit in this especially resistant patient).
The deepest active contacts on both sides (contact 0 on
the left and contact 5 on the right) were located in the
postero-ventral part of the ALIC (see Fig. 1). The
stimulation protocol was conducted exactly the same
way after both surgeries. So, any parameters combin-
ation tested in the 2nd surgery (including low-frequency
paradigms) were also tested after the first implant, with
null results.
After 16 weeks, compulsive behavior began to improve:
YBOCS score fell from 35 to 26, a 32 % improvement
compared with baseline (symptom severity in obsessions
and compulsions decreased in parallel). A Dimensional
Yale-Brown Obsessive-Compulsive Scale (DY-BOCS) was
also scored after second surgery, showing that clinical
improvement occurred mostly in the Aggressive-Checking
dimension (Basal Severity Score: 15 vs Postsurgery
Severity Score: 9, 40 % reduction) and secondly in the
Symmetry-Ordering dimension (Basal Severity Score: 15
vs Postsurgery Severity Score: 10, 33 % reduction). The
patient reports improved quality of life and a stabilization
of daily life routines (in Table 1). Since hospital discharge
(in June 2011) the patient remains stabilized with fluctuat-
ing moderate symptomatology (YBOCS 22 in April 2012,
a 42 % improvement), but he has not needed further
hospital admission.
Discussion
Although there is broad consensus on the neuropatho-
logical correlates of OCD, the search for the “OCD target”
for DBS is still ongoing. Various targets have been chosenwith the aim of modulating activity within the cortico-
striato-thalamo-cortical circuit (CSTC) at one of its
critical nodes. Some of these regions are the ALIC [12],
the nucleus accumbens [13], the ventral caudate nucleus
[14], the VS/VC [11], the inferior thalamic peduncle (ITP)
[15] and the subthalamic nucleus [16], in which differing
therapeutic benefits have been achieved. Clinical outcome
for all studies yields a mean Y-BOCS reduction that ranges
from 45.1 to 47.7 % and a global percentage of responders
of 60 % [17, 18]. Previous evidence supported that reduc-
tions in OCD severity were greater in patients receiving
NAcc and VC/VS stimulation (52-54 %) than in patients
receiving STN stimulation (41 %) (reviewed in [17]). How-
ever, in a recently published meta-analysis comparing the
response to DBS in all available OCD patients worldwide,
no significant differences were detected between targets in
terms of the percentage of reduction in Y-BOCS scores or
in percentage of responders when striatal areas stimula-
tion were compared to STN stimulation [17]. These re-
sults must be taken with caution, as studies are also
heterogeneous in terms of electrode design and stimula-
tion parameters (and patients are also clinically
heterogeneous).
Our patient did not respond satisfactorily to the first
surgery, although the neuroanatomical target used was
similar to that used in other patients enrolled in our DBS
program who did respond. We decided to use a double
strategy for the second surgical procedure. First, we
implanted the lead in a more posterior location. Targeting
a more posterior region of the VS/VC has been associated
with a greater YBOCS reduction [11]. The VS/VC has
been reported to be a node of different CSTC circuits
related with OCD symptoms. Neuromodulation of these
circuits seem to be more effective with a more posterior
location of the DBS electrodes since these circuits become
more compact as they run posteriorly to the thalamus
through the inferior thalamic peduncle (ITP) [11]. Indeed,
in our patient, stimulation seems to be centred on the
anatomical region of the ITP target described by Jimenez
[15].
In the second intervention we also used a larger elec-
trode (Model 3391). This lead was designed to cover the
length of the ALIC (active contact length of 3 mm). It
seems plausible that, if this lead stimulates a wider range
of neuroanatomical areas, the combination of parameters
including the optimum target for this patient is more
likely to be found with the second implant. The final pos-
ition of the active contacts is in close relation with certain
brain structures believed to be involved in pathophysio-
logical aspects of OCD (Fig. 1). The bed nucleus of the
stria terminalis (left side) has been related to anxiety
expression in some experimental models [19], and the
medial forebrain bundle (the deepest active contact on the
right side) is known to be a key structure in the brain’s
Fig. 1 Anatomical location of the stimulation points and postoperative location of the electrodes on both surgeries. Red dots (A,B,D,E) show the
position of the center of the stimulation after the first and second surgery superimposed in Mai atlas*†. a Coronal section 4,2 mm anterior to AC
showing the middle point between the two active contacts on the right side after the first surgery. b Coronal section 5,8 mm anterior to AC
showing the middle point between the two active contacts on the left side after the first surgery. c Postoperative CT fused with MRI showing the
radiological position of the electrodes with respect to anterior comissure after the first surgery. d Coronal section 4,0 mm posterior to AC
showing the middle point between the two active contacts on the right side after the second surgery. e Coronal section 2,7 mm posterior to AC
showing the middle point between the two active contacts on the left side after the second surgery. f Postoperative CT fused with MRI showing
radiological position of the electrodes with respect to anterior comissure after the second surgery. * Images on both sides correspond to frontal
sections of left hemispheres of the human brain in Mai atlas. Frontal sections most closely related with anatomical location of the stimulation point
have been chosen for the figure. † Elsevier Ltd. granted written permission to use, adapt and publish the images belonging to Atlas of the Human
Brain, 3° ed (ISBN 9780123736031), Mai et al.
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sive behavior [20]. Although it is speculative, this could
lead us to hypothesize that different subgroups of OCD
(according to phenotypic differences) could respond better
depending on the target stimulated. Unfortunately,
data available in literature does not allow drawing re-
liable conclusions on this issue due to several reasons:
the number of patients included in OCD DBS studies
are insufficient to allow comparisons between targets,
OCD DBS studies differ in electrode design and
stimulation protocols used (which also hampers thecomparison between clinical issues and targets), and
current magnetic resonance imaging does not have
enough resolution to find differences between NAcc
and VC/VS (which are very close).
The therapeutical response after the second surgery was
moderate despite optimal anatomic placement, and mul-
tiple stimulation parameter settings were performed for
several months (monopolar, bipolar, stimulation of mul-
tiple contacts). This particularly resistant profile observed
in some patients has been ascribed to an individual re-
sponse to DBS, according to differential clinical features
Real et al. BMC Psychiatry  (2016) 16:26 Page 5 of 7and patterns of connectivity (reviewed in Lipsman) [21]. It
has been reported that ‘just-right’ experiences or the need
for symmetry exhibited by our patient may be less likely
to respond to DBS [22, 23]. Moreover, early onset OCD
has been associated to a worse response to DBS when all
targets are considered as a whole [17]. Regarding the exist-
ence of differential patterns of connectivity, the use of
neuroimaging techniques such as diffusion tensor imaging
(DTI)-based tractography has been proposed to identify
the precise trajectory of tracts at a single subject level in
depression [24].
The patient described became a responder after reim-
plantation of DBS electrodes in the VS/VC target in a
more posterior location. The stimulation of different
brain areas after an unsuccessful implantation has been
previously described in Tourette syndrome patients with
severe comorbid OCD (adding bilateral ALIC/NAcc re-
gion DBS leads to the existing Vo/CM-Pf stimulation or
through de novo ALIC/NAcc DBS plus Vo/CM-Pf re-
gion stimulation) [25]. However, the explantation and
reimplantation of DBS devices has not been previously
reported in the literature for therapeutical benefits in
resistant OCD.
The experience of our case brings us back to the de-
bate on which is the best target for OCD, as the stimula-
tion of both targets (NAcc and VC/VS) have been
reported to be effective in resistant patients. They are
very close and one could think that the stimulation of
one would influence the activity of the other, as they are
critical nodes within the CSTC circuit. Evidence in the
literature does not allow us to know why our patient did
not benefit from the first implantation in NAcc (al-
though he did from the second implantation, in VC/VS)
nor why he responded while receiving low frequency
DBS. Although it is speculative, it cannot be discarded
that some targets might be more sensitive to electric
stimulation than others (due to still unknown mecha-
nisms). It would be similar to the fact that some patients
respond to certain selective serotonin reuptake inhibitors
(SSRIs), but not to others (when all drugs belong to the
same family and theoretically share the same mechanism
of action). The target selection is further complicated, as
it has been demonstrated with neuroimaging data that
even within the same NAcc, the actual stimulation coor-
dinates vary substantially between patients, which sig-
nificantly influence on clinical outcomes [26]. So,
depending on the specific stimulation site, different
fiber bundles and therefore different sets of structures
may be affected [11]. From an electrophysiological
point of view, stimulation both hyperpolarize and
depolarize neurons and activation of axons may have
distal effects, including overall excitation or inhibition
through stimulation of inhibitory neurons. This indi-
cates that DBS may evoke multiple effects (reviewedin [27]). The benefits of low-frequency DBS has been
reported in animal models of OCD. The 8-OHDPAT-
induced decreased alternation model might serve to
model two specific aspects of OCD, namely persever-
ation and indecision (reviewed in [17]). In this rat
model, low- but not high-frequency stimulation (HFS)
of the thalamic nucleus is effective in reducing 8-
OHDPAT-induced perseveration [28] whereas HFS of
the STN has shown anti-OCD effects in humans [29].
Future research will help to integrate findings coming
from different research approaches.
Some weaknesses might be considered: 1) potential
effects of other concurrent interventions performed
when the patient responded (besides the explantation
and the stimulation of a new target) cannot be dis-
carded. This interventions include slight changes in
medication, change in type of electrodes, changes in
stimulation parameters and possibly a change in vol-
ume of tissue activated (VTA) post surgery 1 vs post
surgery 2. Unfortunately, we are unable to ensure in
which extent these interventions were involved in the
clinical benefit. We think that VTA in second surgery
represented a smaller contribution in clinical improve-
ment. Although we cannot estimate the VTA directly,
we have calculated charge densities in first and second
surgeries (this parameter is proportional to VTA),
resulting that it was about half in the second surgery,
compared to the first surgery (data to perform the cal-
culation are available at the Table 1). On the other
hand, although some reports suggest that DBS may
allow previously ineffective pharmacological treatments
to become effective [30], it is difficult for the authors to
assume that the rise of the dose of an SSRI drug may
be responsible for the improvement of a patient who
did not respond to very potent drugs as phenelzine or
clomipramine at full doses; 2) On the other hand, a
morphing of the atlas to the patient’s own landmarks
was not performed to determine anatomic localization
of the target. However, the authors believe that this did
not affect significantly to the accuracy of the final posi-
tioning of leads.
Conclusions
Our report emphasizes the reversibility profile of DBS,
and helps to dissociate it from the historical negative
connotations of psychosurgery. Following up a patient
with persisting disabling symptoms and very poor qual-
ity of life implies an ethical and clinical dilemma, espe-
cially when the alternative of a second surgery is not
exempt from risks. Although the experience of a case
cannot be extrapolated to another, the authors believe
that a second surgery could be considered after
18 months of non-response to the first surgery in OCD
resistant patients (when all programming possibilities
Real et al. BMC Psychiatry  (2016) 16:26 Page 6 of 7have been exhausted). The capability for explantation
and reimplantation of DBS leads should be considered
as part of DBS reversibility profile in resistant mental
disorders, as it allows application in cases of non-
response to the first surgery.
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